Tepotinib
- Generic Name
- Tepotinib
- Brand Names
- Tepmetko
- Drug Type
- Small Molecule
- Chemical Formula
- C29H28N6O2
- CAS Number
- 1100598-32-0
- Unique Ingredient Identifier
- 1IJV77EI07
- Background
Tepotinib is a MET tyrosine kinase inhibitor intended to treat a variety of MET-overexpressing solid tumors. It was originally developed in partnership between EMD Serono and the University of Texas M.D. Anderson Cancer Center in 2009 and has since been investigated in the treatment of neuroblastoma, gastric cancers, non-small cell lung cancer, and hepatocel...
- Indication
Tepotinib is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) who have mesenchymal-epithelial transition (MET) exon 14 skipping alterations.
- Associated Conditions
- Metastatic Non-Small Cell Lung Cancer
- Associated Therapies
- -
Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment
- Conditions
- Interventions
- First Posted Date
- 2023-10-30
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 47
- Registration Number
- NCT06106802
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Gangnam-gu, Korea, Republic of
PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer
- First Posted Date
- 2023-10-16
- Last Posted Date
- 2024-06-21
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 60
- Registration Number
- NCT06083857
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)
- First Posted Date
- 2023-09-11
- Last Posted Date
- 2024-10-02
- Lead Sponsor
- SWOG Cancer Research Network
- Target Recruit Count
- 56
- Registration Number
- NCT06031688
- Locations
- 🇺🇸
Kaiser Permanente-Bellflower, Bellflower, California, United States
🇺🇸Smilow Cancer Hospital Care Center at Glastonbury, Glastonbury, Connecticut, United States
🇺🇸Alta Bates Summit Medical Center-Herrick Campus, Berkeley, California, United States
POTENT - Tepotinib in Combination with Pembrolizumab in NSCLC
- Conditions
- Interventions
- First Posted Date
- 2023-03-23
- Last Posted Date
- 2024-10-01
- Lead Sponsor
- Institute of Cancer Research, United Kingdom
- Target Recruit Count
- 38
- Registration Number
- NCT05782361
- Locations
- 🇬🇧
DDU, Royal Marsden Hospital NHS Foundation Trust, Sutton, Surrey, United Kingdom
🇬🇧University College London Hospitals NHS Foundation Trust, London, United Kingdom
🇬🇧Lung Unit, Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom
Tepotinib Drug-Drug Interaction Study With Carbamazepine in Healthy Participants
- First Posted Date
- 2022-01-28
- Last Posted Date
- 2024-03-08
- Lead Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 18
- Registration Number
- NCT05213481
- Locations
- 🇩🇪
Nuvisan GmbH, Neu-Ulm, Germany
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
- Conditions
- Interventions
- First Posted Date
- 2021-12-16
- Last Posted Date
- 2024-07-15
- Lead Sponsor
- Helsinki University Central Hospital
- Target Recruit Count
- 250
- Registration Number
- NCT05159245
- Locations
- 🇫🇮
Turku University Hospital Cancer Centre, Turku, Varsinais-Suomi, Finland
🇫🇮Kuopio University Hospital, Kuopio, Finland
🇫🇮Oulu University Hospital OYS Cancer Center, Oulu, Finland
A Phase 1a/1b Study to Determine the Recommended Phase 2 Dose, of Tepotinib in Participants With MET Alterations and Brain Tumors
- First Posted Date
- 2021-11-16
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05120960
CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC
- Conditions
- Interventions
- First Posted Date
- 2021-02-04
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Criterium, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT04739358
- Locations
- 🇺🇸
University of Colorado Cancer Center, Aurora, Colorado, United States
🇺🇸Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
🇺🇸UC Davis Comprehensive Cancer Center, Sacramento, California, United States
Tepotinib in Solid Tumors Harboring MET Alterations
- Conditions
- Interventions
- First Posted Date
- 2020-12-01
- Last Posted Date
- 2020-12-02
- Lead Sponsor
- Chungbuk National University Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT04647838
- Locations
- 🇰🇷
Konyang University Hospital, Daejeon, Korea, Republic of
🇰🇷Seoul National University Bundang Hospital, Seongnam-si, Korea, Republic of
🇰🇷Pusan National University Yangsan Hospital, Yangsan, Korea, Republic of
The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy
- Conditions
- Interventions
- Drug: Oncology DrugsDrug: ErlotinibDrug: TrastuzumabDrug: Trastuzumab emtansineDrug: PertuzumabDrug: LapatinibDrug: EverolimusDrug: VemurafenibDrug: CobimetinibDrug: AlectinibDrug: BrigatinibDrug: PalbociclibDrug: PonatinibDrug: VismogedibDrug: ItacitinibDrug: IpatasertibDrug: EntrectinibDrug: AtezolizumabDrug: NivolumabDrug: IpilimumabDrug: PemigatinibDrug: PralsetinibDrug: SelpercatinibDrug: TalazoparibDrug: TepotinibDrug: Alpelisib
- First Posted Date
- 2020-10-19
- Last Posted Date
- 2023-10-03
- Lead Sponsor
- Fondazione per la Medicina Personalizzata
- Target Recruit Count
- 400
- Registration Number
- NCT04591431
- Locations
- 🇮🇹
I.R.S.T. Srl Irccs, Meldola, Italy
🇮🇹Ospedale Classificato Sacro Cuore - Don Calabria, Negrar, Italy
🇮🇹I.R.C.C.S. Istituto Oncologico Veneto, Padova, Italy
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.